Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer

Executive Summary

Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology. 

You may also be interested in...



Biotechs Face Daunting Launch Environment Going It Alone

Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.

Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel